
Collegium Pharmaceutical Inc
NASDAQ:COLL

Operating Margin
Collegium Pharmaceutical Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
![]() |
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
1B USD |
20%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
735.9B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
45%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
202.1B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
178.4B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.5B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
205.3B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.9B USD |
27%
|
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Collegium Pharmaceutical Inc's most recent financial statements, the company has Operating Margin of 19.7%.